Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01555151
First received: March 13, 2012
Last updated: September 14, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to compare the efficacy, safety and pharmacokinetics of Mometasone furoate delivered via Concept1 device or Twisthaler® device in adult and adolescent patients with persistent asthma.


Condition Intervention Phase
Asthma
Drug: Mometasone furoate
Device: Concept 1
Device: Twisthaler
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Double-dummy, 4-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of Two Doses of Mometasone Furoate Delivered Via Concept1 or Twisthaler® in Adult and Adolescent Patients With Persistent Asthma

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Trough Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Day 29 ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on day 29 after treatment.


Secondary Outcome Measures:
  • Trough Forced Expiratory Volume in 1 Second (FEV1) After Days 8, 15 and 22 of Treatment [ Time Frame: Days 8, 15 and 22 ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards. Measurements were taken on days 8, 15 and 22 after treatment. Data within 6 hr of rescue medication use is excluded from this analysis.

  • Forced Vital Capacity (FVC) at All Time Points [ Time Frame: Days 1, 8, 15, 22, 28 and 29 at all time points ] [ Designated as safety issue: No ]
    Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data within 6 hr of rescue medication use is excluded from this analysis. Mixed model: FVC = treatment + gender+ baseline FVC + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.

  • Forced Expiratory Flow Between 25% and 75% (FEF25-75%) at All Time Points [ Time Frame: Days 1, 8, 15, 22, 28 and 29 at all time points ] [ Designated as safety issue: No ]
    The Forced Expiratory Flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.

  • Forced Expiratory Volume in 1 Second Forced Vital Capacity (FEV1/FVC) Percent at All Time Points [ Time Frame: Days 1, 8, 15, 22, 28 and 29 at all time points ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards. Data within 6 hr of rescue medication use is excluded from this analysis.

  • Change From Baseline in Mean Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 4 Weeks of Treatment [ Time Frame: Baseline and week 4 ] [ Designated as safety issue: No ]
    Peak expiratory flow rate (PEFR) was measured via electronice Peak flow meter by patient at home. Mixed model used: change from baseline in the mean evening PEFR = treatment + age + gender + baseline evening PEFR + level of asthma control + region + center (region)+ error. Center is included as a random effect nested within region.

  • Change From Baseline in Asthma Control Questionnaire (ACQ-5) by Visit [ Time Frame: Baseline, days 8,15,22 and 29 ] [ Designated as safety issue: No ]
    Asthma symptoms were evaluated by the Asthma Control Questionnaire (ACQ). The ACQ-5 has five questions of the asthma symptoms to be answered by the patient. The overall score is the average of the 5 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma. A negative change in score indicates improvement in symptoms. MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region. - Baseline ACQ-5 is defined as the questionnaire completed on Day 1 (randomization).

  • Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over 4 Weeks of Treatment [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
    Rescue medication data recorded during the 14 day run-in period is used to calculate the baseline. - Total number of puffs of rescue medication per day over the full 4 weeks is calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the subject. - MIXED model: Change = treatment + gender + baseline mean daily number of puffs + age + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.

  • Percentage of Days With no Rescue Medication Use Over 4 Weeks of Treatment [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

    Mixed model used: percentage of days with no rescue medication use = treatment + age + gender + baseline percentage of days with no rescue use + level of asthma control + region + center (region) + error. Center is included as a random effect nested within region.

    A day with no rescue use is defined from diary data as any day where the subject does not use any puffs of rescue medication.

    The total number of days with no rescue use over the 4 week treatment period is divided by the total number of evaluable days in order to derive the percentage of days with no rescue use.


  • Fractional Exhaled Nitric Oxide (FeNO) [ Time Frame: Days 15 and 29 ] [ Designated as safety issue: No ]
    FeNO is widely accepted as a non-invasive marker for airway inflammation such as asthma and conducted according to published guideline. FeNO was measured on days 15 and 29 after treatment.

  • Plasma Cortisol Concentrations [ Time Frame: Baseline, days 1 and 28 ] [ Designated as safety issue: Yes ]
    Blood samples were taken from each subject participating in the study post dose at day 1 and week 4. Cortisol concentrations were evaluated. Results are presented as nmol/L


Enrollment: 739
Study Start Date: July 2012
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mometasone furoate 80 μg
Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
Drug: Mometasone furoate
Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
Other Name: QMF149
Device: Concept 1
A single dose dry powder inhaler (SDDPI)
Experimental: Mometasone furoate 200 µg
Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
Drug: Mometasone furoate
Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
Other Name: QMF149
Device: Twisthaler
A single dose dry powder inhaler (SDDPI)
Experimental: Mometasone furoate 320 µg
Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
Drug: Mometasone furoate
Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
Other Name: QMF149
Device: Concept 1
A single dose dry powder inhaler (SDDPI)
Experimental: Mometasone furoate 800 µg
Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
Drug: Mometasone furoate
Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
Other Name: QMF149
Device: Twisthaler
A single dose dry powder inhaler (SDDPI)

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females who were ≥ 12 years old at the time informed consent was obtained
  • Patients with persistent asthma, diagnosed according to GINA 2010 guideline and who additionally met the following criteria
  • Patients who were receiving ICS treatment up to the maximum dose per day as indicated in the corresponding package leaflet and also a stable ICS regimen for at least 4 weeks prior to screening (Visit 2).
  • Patients whose level of asthma control according to GINA 2010 guideline was "Partly Controlled" or "Uncontrolled" at screening (Visit 2).
  • Patients with a pre-bronchodilator FEV1 value of ≤ 80% of predicted normal value at screening (Visit 2).
  • Patients who demonstrated an increase of ≥ 12% and 200 mL in FEV1 over prebronchodilator value within 30 minutes after inhalation of 400 μg of salbutamol (360 μg of albuterol) at Visit 2 or between Visit 2 and Visit 5.
  • Patients who were confirmed as "ICS sensitive" by ACQ-5 and FEV1 at Visit 5.

Key exclusion criteria included:

  • Patients diagnosed with COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease, updated 2010.
  • Patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed by chest X-ray to be no longer active), or clinically significant bronchiectasis.
  • Patients with any chronic conditions affecting the respiratory tract (e.g., chronic sinusitis) or chronic lung diseases, which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.
  • Patients with seasonal allergy which is likely to deteriorate his/her asthma condition during the study period judged by the investigator.
  • Patients who have had a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to Visit 1 or any time between Visit 1 and Visit 5 must discontinue from the trial (screening failure).
  • Patients who have had an emergency room visit for an asthma attack/exacerbation within 4 weeks prior to Visit 1 or any time between Visit 1 and Visit 5 must discontinue from the trial (screening failure).
  • Patients who have ever required intubation for a severe asthma attack/exacerbation.
  • Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1, or any time between Visit 1 and Visit 5 must discontinue from the trial (screening failure).

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01555151

  Hide Study Locations
Locations
Belgium
Novartis Investigative Site
Kortrijk, Belgium, 8500
Novartis Investigative Site
Liège, Belgium, 4000
Canada, Ontario
Novartis Investigative Site
Niagara Falls, Ontario, Canada, L2G 1J4
Novartis Investigative Site
Windsor, Ontario, Canada, N8X 5A6
Canada, Quebec
Novartis Investigative Site
Mirabel, Quebec, Canada, J7J 2K8
Novartis Investigative Site
Montreal, Quebec, Canada, H3G 1L5
Novartis Investigative Site
Trois-Rivières, Quebec, Canada, G8T 7A1
Canada
Novartis Investigative Site
Quebec, Canada, GIV 4M6
Estonia
Novartis Investigative Site
Kohtla-Järve, Estonia, 30321
Novartis Investigative Site
Tallinn, Estonia, 10138
Novartis Investigative Site
Tartu, Estonia, 51014
Germany
Novartis Investigative Site
Berlin, Germany, 10696
Novartis Investigative Site
Berlin, Germany, 14057
Novartis Investigative Site
Berlin, Germany, 14050
Novartis Investigative Site
Berlin, Germany, 10117
Novartis Investigative Site
Berlin, Germany, 10717
Novartis Investigative Site
Berlin, Germany, 12203
Novartis Investigative Site
Dresden, Germany, 01069
Novartis Investigative Site
Essen, Germany, 45355
Novartis Investigative Site
Goch, Germany, 47574
Novartis Investigative Site
Hamburg, Germany, 22143
Novartis Investigative Site
Hamburg, Germany, 20253
Novartis Investigative Site
Hannover, Germany, 30317
Novartis Investigative Site
Leipzig, Germany, 4207
Novartis Investigative Site
Luebeck, Germany, 23562
Novartis Investigative Site
Muenchen, Germany, 80539
Novartis Investigative Site
Reinfeld, Germany, 23858
Novartis Investigative Site
Schwerin, Germany, 19055
Hungary
Novartis Investigative Site
Baja, Hungary, 6500
Novartis Investigative Site
Balassagyarmat, Hungary, 2660
Novartis Investigative Site
Budapest, Hungary, 1135
Novartis Investigative Site
Budapest, Hungary, 1121
Novartis Investigative Site
Budapest, Hungary, 1036
Novartis Investigative Site
Budapest, Hungary, 1122
Novartis Investigative Site
Budapest, Hungary, 1033
Novartis Investigative Site
Budapest, Hungary, 1041
Novartis Investigative Site
Cegled, Hungary, 2700
Novartis Investigative Site
Debrecen, Hungary, 4031
Novartis Investigative Site
Godollo, Hungary, 2100
Novartis Investigative Site
Gyor, Hungary, 9024
Novartis Investigative Site
Gyula, Hungary, 5703
Novartis Investigative Site
Kistelek, Hungary, 6760
Novartis Investigative Site
Komarom, Hungary, 2900
Novartis Investigative Site
Makó, Hungary, 6900
Novartis Investigative Site
Mohacs, Hungary, 7700
Novartis Investigative Site
Monor, Hungary, 2200
Novartis Investigative Site
Mosonmagyarovar, Hungary, 9200
Novartis Investigative Site
Nagykanizsa, Hungary, 8800
Novartis Investigative Site
Nyiregyhaza, Hungary, 4400
Novartis Investigative Site
Szeged, Hungary, 6722
Novartis Investigative Site
Szikszo, Hungary, 3800
Novartis Investigative Site
Szombathely, Hungary, 9700
Novartis Investigative Site
Százhalombatta, Hungary, 2440
Novartis Investigative Site
Torokbalint, Hungary, 2045
India
Novartis Investigative Site
Bangalore, Karnataka, India, 560043
Novartis Investigative Site
Bangalore, Karnataka, India, 560054
Novartis Investigative Site
Bangalore, Karnataka, India, 560 010
Novartis Investigative Site
Mysore, Karnataka, India, 570004
Novartis Investigative Site
Pune, Maharashtra, India, 411 014
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641 045.
Novartis Investigative Site
Vellore, Tamil Nadu, India, 632 004
Novartis Investigative Site
Jaipur, India, 302001
Novartis Investigative Site
Karamsad, India, 388225
Novartis Investigative Site
Ludhiana, India, 141001
Novartis Investigative Site
Nagpur, India, 400012
Novartis Investigative Site
Thrissur, India, 680002
Japan
Novartis Investigative Site
Toon-shi, Ehime, Japan, 791-0281
Novartis Investigative Site
Mizunami-city, Gifu, Japan, 509-6134
Novartis Investigative Site
Fukuyama-shi, Hiroshima, Japan, 720-0001
Novartis Investigative Site
Kitahiroshima-shi, Hokkaido, Japan, 061-1121
Novartis Investigative Site
Obihiro-shi, Hokkaido, Japan, 080-0013
Novartis Investigative Site
Obihiro-shi, Hokkaido, Japan, 080-0805
Novartis Investigative Site
Sapporo-shi, Hokkaido, Japan, 065-0025
Novartis Investigative Site
Sapporo-shi, Hokkaido, Japan, 004-0022
Novartis Investigative Site
Tomakomai, Hokkaido, Japan, 053-8506
Novartis Investigative Site
Kobe-shi, Hyogo, Japan, 653-0021
Novartis Investigative Site
Kawasaki-shi, Kanagawa, Japan, 211-0041
Novartis Investigative Site
Kurashiki-city, Okayama, Japan, 712-8064
Novartis Investigative Site
Kurashiki-shi, Okayama, Japan, 713-8103
Novartis Investigative Site
Osaka-city, Osaka, Japan, 530-0001
Novartis Investigative Site
Sakai-city, Osaka, Japan, 591-8555
Novartis Investigative Site
Suita, Osaka, Japan, 565-0853
Novartis Investigative Site
Toyonaka-city, Osaka, Japan, 560-0082
Novartis Investigative Site
Chiyoda-ku, Tokyo, Japan, 102-0083
Novartis Investigative Site
Chuo-ku, Tokyo, Japan, 103-0027
Novartis Investigative Site
Chuo-ku, Tokyo, Japan, 103-0028
Novartis Investigative Site
Hachioji-city, Tokyo, Japan, 192-0032
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan, 140-0011
Novartis Investigative Site
Tachikawa, Tokyo, Japan, 190-0013
Novartis Investigative Site
Toshima-ku, Tokyo, Japan, 171-0014
Latvia
Novartis Investigative Site
Rezekne, LV, Latvia, LV-4600
Novartis Investigative Site
Riga, LV, Latvia, 1002
Novartis Investigative Site
Talsi, LV, Latvia, LV3201
Novartis Investigative Site
Riga, Latvia, LV-1004
Novartis Investigative Site
Riga, Latvia, LV-1038
Novartis Investigative Site
Riga, Latvia, 1002
Lithuania
Novartis Investigative Site
Kaunas, LT, Lithuania, 44320
Novartis Investigative Site
Klaipeda, LT, Lithuania, 92288
Novartis Investigative Site
Kaunas, Lithuania, 50009
Novartis Investigative Site
Klaipeda, Lithuania, LT-92231
Novartis Investigative Site
Vilnius, Lithuania, LT-08661
Malaysia
Novartis Investigative Site
Kuching, Sarawak, Malaysia, 93586
Novartis Investigative Site
Kota Kinabalu, Malaysia, 88586
Novartis Investigative Site
Kuala Lumpur, Malaysia, 59100
Netherlands
Novartis Investigative Site
Almere, The Netherlands, Netherlands, 1311 RL
Novartis Investigative Site
Eindhoven, The Netherlands, Netherlands, 5616GB
Novartis Investigative Site
Leiderdorp, The Netherlands, Netherlands, 2352 RA
Novartis Investigative Site
Rotterdam, The Netherlands, Netherlands, 3021 HC
Novartis Investigative Site
Zoetermeer, The Netherlands, Netherlands, 2724 EK
Novartis Investigative Site
Geleen, Netherlands, 6166 GR
Novartis Investigative Site
Hoofddorp, Netherlands, 2134 TM
Poland
Novartis Investigative Site
Bialystok, Poland, 15-445
Novartis Investigative Site
Gdansk, Poland, 80-952
Novartis Investigative Site
Katowice, Poland, 40-954
Novartis Investigative Site
Krakow, Poland, 30-510
Novartis Investigative Site
Krakow, Poland, 31-637
Novartis Investigative Site
Lodz, Poland, 95-100
Novartis Investigative Site
Poznan, Poland, 60-693
Novartis Investigative Site
Skierniewice, Poland, 96-100
Novartis Investigative Site
Warszawa, Poland, 01-868
Novartis Investigative Site
Wroclaw, Poland, 50-445
Russian Federation
Novartis Investigative Site
St. Petersburg, Nizhny Novgorod, Russian Federation, 194356
Novartis Investigative Site
Ekaterinburg, Russia, Russian Federation, 620109
Novartis Investigative Site
Kazan, Russia, Russian Federation, 420012
Novartis Investigative Site
Moscow, Russia, Russian Federation, 109240
Novartis Investigative Site
Sankt-Peterburg, Russia, Russian Federation, 197022
Novartis Investigative Site
St. Petersburg, Russia, Russian Federation, 194044
Novartis Investigative Site
Yaroslavl, Russian Federation, 150003
Slovakia
Novartis Investigative Site
Bojnice, Slovak Republic, Slovakia, 972 01
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia, 83101
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia, 831 03
Novartis Investigative Site
Kosice, Slovak Republic, Slovakia, 040 01
Novartis Investigative Site
Levice, Slovak republic, Slovakia, 934 01
Novartis Investigative Site
Liptovsky Hradok, Slovak Republic, Slovakia, 033 01
Novartis Investigative Site
Nitra, Slovak Republic, Slovakia, 949 01
Novartis Investigative Site
Roznava, Slovak Republic, Slovakia, 4801
Novartis Investigative Site
Surany, Slovak Republic, Slovakia, 942 01
Novartis Investigative Site
Trencin, Slovak Republic, Slovakia, 91108
Novartis Investigative Site
Bratislava, Slovakia, 833 40
Novartis Investigative Site
Martin, Slovakia, 036 59
Novartis Investigative Site
Poprad, Slovakia, 05845
Novartis Investigative Site
Ruzomberok, Slovakia, 034 26
Thailand
Novartis Investigative Site
Muang, Thailand, 30000
Novartis Investigative Site
Muang, Thailand, 11000
Novartis Investigative Site
Rajathevee, Thailand, 10400
Novartis Investigative Site
Ratchathewi, Thailand, 10400
Turkey
Novartis Investigative Site
Adana, Turkey, 01330
Novartis Investigative Site
Bursa, Turkey, 16059
Novartis Investigative Site
Gaziantep, Turkey, 27310
Novartis Investigative Site
Istanbul, Turkey, 35100
Novartis Investigative Site
Izmir, Turkey, 35040
Novartis Investigative Site
Izmir, Turkey, 34890
Novartis Investigative Site
Talas / Kayseri, Turkey, 38039
Ukraine
Novartis Investigative Site
Dnipropetrovsk, Ukraine, 49066
Novartis Investigative Site
Dnipropetrovsk, Ukraine, 49051
Novartis Investigative Site
Donetsk, Ukraine, 83003
Novartis Investigative Site
Kharkiv, Ukraine, 61039
Novartis Investigative Site
Kharkiv, Ukraine, 61098
Novartis Investigative Site
Kharkiv, Ukraine, 49066
Novartis Investigative Site
Kyiv, Ukraine, 4050
Novartis Investigative Site
Kyiv, Ukraine, 3680
Novartis Investigative Site
Kyiv, Ukraine, 1004
Novartis Investigative Site
Kyiv, Ukraine, 6115
Novartis Investigative Site
Vinnytsia, Ukraine, 20129
Novartis Investigative Site
Vinnytsia, Ukraine, 21029
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01555151     History of Changes
Other Study ID Numbers: CQMF149E2201, 2011-005100-14
Study First Received: March 13, 2012
Results First Received: July 6, 2014
Last Updated: September 14, 2014
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
Estonia: The State Agency of Medicine
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute for Quality - and Organizational Development in Healthcare and Medicines/National Institute of Pharmacy
India: Drugs Controller General of India
Japan: Pharmaceuticals and Medical Devices Agency
Latvia: State Agency of Medicines
Lithuania: State Medicine Control Agency - Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Expert Board (FSBI Scientific Center of Medical Application Expertise of Ministry of Health and Social Development of the Russian Federation)
Slovakia: State Institute for Drug Con
Thailand: Food and Drug Administration
Turkey: Ministry of Health
Ukraine: Ministry of Health

Keywords provided by Novartis:
Asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Mometasone furoate
Anti-Allergic Agents
Anti-Inflammatory Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 30, 2014